Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -18.25
- Piotroski Score 2.00
- Grade Buy
- Symbol (KALA)
- Company Kala Pharmaceuticals, Inc.
- Price $6.55
- Changes Percentage (-2.24%)
- Change -$0.15
- Day Low $6.45
- Day High $6.82
- Year High $10.97
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $15.00
- High Stock Price Target $15.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$14.56
- Trailing P/E Ratio -0.45
- Forward P/E Ratio -0.45
- P/E Growth -0.45
- Net Income $-42,199,000
Income Statement
Quarterly
Annual
Latest News of KALA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
NRC and YIT to begin construction of Pirkkala-Linnainmaa tramway in Finland
The first phase of the Pirkkala-Linnainmaa tramway construction in Tampere, Finland, has been awarded to NRC Group Finland and YIT Finland....
By Yahoo! Finance | 3 weeks ago -
UFC 308 Preview, Odds, Picks And Predictions: Ankalaev Vs. Rakic
UFC 308 features a stacked fight card on October 26, with Topuria vs. Holloway and Whittaker vs. Chimaev headlining. A pivotal light heavyweight bout between Ankalaev and Rakic will determine the next...
By Forbes | 4 weeks ago -
Meera Sodha's vegan recipe for fennel, artichoke, potato and kalamata olive stew | The new vegan
A Mediterranean-inspired stew recipe filled with comforting ingredients, perfect for autumn. The stew is sweetly spiced, hearty, and flavorful, making it a satisfying and balanced meal. Serve with cru...
By The Guardian | 4 weeks ago
